Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders
AbstractThe effector functions of T lymphocytes are responsible for most autoimmune disorders and act by directly damaging tissues or by indirectly promoting inflammation and antibody responses. Co-stimulatory and co-inhibitory T cell receptor molecules are the primary pharmacological targets that enable interference with immune-mediated diseases. Among these, selective CD28 antagonists have drawn special interest, since they tip the co-stimulation/co-inhibition balance towards efficiently inhibiting effector T cells while promoting suppression by pre-existing regulatory T-cells. After having demonstrated outstanding therapeutic efficacy in multiple models of autoimmunity, inflammation and transplantation, and safety in phase-I studies in humans, selective CD28 antagonists are currently in early clinical development for the treatment of systemic lupus erythematous and rheumatoid arthritis. Here, we review the available proof of concept studies for CD28 antagonists in autoimmunity, with a special focus on the mechanisms of action. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Vanhove, B.; Poirier, N.; Fakhouri, F.; Laurent, L.; ’t Hart, B.; Papotto, P.H.; Rizzo, L.V.; Zaitsu, M.; Issa, F.; Wood, K.; Soulillou, J.-P.; Blancho, G. Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders. Antibodies 2017, 6, 19.
Vanhove B, Poirier N, Fakhouri F, Laurent L, ’t Hart B, Papotto PH, Rizzo LV, Zaitsu M, Issa F, Wood K, Soulillou J-P, Blancho G. Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders. Antibodies. 2017; 6(4):19.Chicago/Turabian Style
Vanhove, Bernard; Poirier, Nicolas; Fakhouri, Fadi; Laurent, Laetitia; ’t Hart, Bert; Papotto, Pedro H.; Rizzo, Luiz V.; Zaitsu, Masaaki; Issa, Fadi; Wood, Kathryn; Soulillou, Jean-Paul; Blancho, Gilles. 2017. "Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders." Antibodies 6, no. 4: 19.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.